Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 2 Study Evaluating the Safety and Efficacy of Whole-Cell Pneumococcal Vaccine (wSp) in Reducing Nasopharyngeal Colonization by Streptococcus Pneumoniae in Young Children.

NCT07216430 is registered in ClinicalTrials.gov with Serum Life Science Europe GmbH as lead sponsor.

NCT NCT07216430
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07216430 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 2 Study Evaluating the Safety and Efficacy of Whole-Cell Pneumococcal Vaccine (wSp) in Reducing Nasopharyngeal Colonization by Streptococcus Pneumoniae in Young Children.
Lead sponsor
Serum Life Science Europe GmbH
Phase
Phase 2
Overall status
Recruiting
Start date
September 29, 2025
Completion date
June 30, 2029
Enrollment
320 (estimated)
Sites
7

Conditions

As the registry lists them; a condition with its own page is linked.

acute otitis media (aom)